

Date: 12/07/2016

FREEDOM OF INFORMATION REQUEST FOI/012838 – biologics and biosimilars

Could you please provide me with the following numbers of patients treated in the last six months (to date) with the following drugs for the conditions listed below?

	Rheumatoid arthritis	Ankylosing spondylitis	Psoriatic arthritis
Abatacept (Orencia)	24	0	0
Adalimumab (Humira)	96	48	50
Apremilast (Otezla)	0	0	0
Certolizumab Pegol (Cimzia)	17	0	0
Etanercept (Enbrel)	190 unable to break down	0	0
Etanercept biosimilar (Benepali)	3	0	0
Golimumab (Simponi)	18	9	11
Infliximab (Remicade)	15	0	0
Infliximab biosimilar (Inflectra)	0	0	0
Infliximab biosimilar (Remsima)	0	0	0
Rituximab (MabThera)	56	0	0
Secukinumab (Cosentyx)	0	0	0
Ixekizumab (Taltz)	0	0	0
Tocilizumab (RoActemra)	29	0	0
Ustekinumab (Stelara)	2	0	0
Vedolizumab (Entyvio)	0	0	0